Our Clinical Trials
Duvelisib
We are working to expand our flagship therapy, duvelisib, into additional cancer types.
We successfully conducted large Phase 2 trials in peripheral T cell lymphoma (PTCL) and indolent Non-Hodgkin Lymphoma to build on work performed by the drug’s originator. Our ongoing clinical work homes in on a subpopulation of high-responding PTCL patients with nodal T Cell Lymphoma with T Follicular Helper (TFH) phenotype.
The information presented above does not make any claims with regard to safety or efficacy. There are no guarantees that the outcomes of these studies will result in regulatory approval(s).
Expanded Access
Secura Bio believes that the best way to access its investigational products is through one of its clinical trials. At this time, Secura Bio is not able to grant requests for expanded access to its investigational therapies.
For more information on Secura Bio’s clinical trials that may be recruiting, search Secura Bio at www.clinicaltrials.gov.
Contact Information: A treating physician may request additional information about Secura Bio’s clinical trials via email at the following address: EAPInquiries@securabio.com
The posting of this policy by Secura Bio shall not serve as a guarantee of access to any specific investigational drug by any individual patient.
Secura Bio may revise this expanded access policy at any time. This posting will be updated should there be any policy change.